Does MOSUNETUZUMAB Cause Therapy partial responder? 26 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Therapy partial responder have been filed in association with MOSUNETUZUMAB (Lunsumio Velo). This represents 5.1% of all adverse event reports for MOSUNETUZUMAB.
26
Reports of Therapy partial responder with MOSUNETUZUMAB
5.1%
of all MOSUNETUZUMAB reports
25
Deaths
0
Hospitalizations
How Dangerous Is Therapy partial responder From MOSUNETUZUMAB?
Of the 26 reports, 25 (96.2%) resulted in death.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOSUNETUZUMAB. However, 26 reports have been filed with the FAERS database.
What Other Side Effects Does MOSUNETUZUMAB Cause?
Cytokine release syndrome (96)
Disease progression (65)
Covid-19 (50)
Neutropenia (39)
Death (38)
Covid-19 pneumonia (37)
Malignant neoplasm progression (37)
Disorientation (31)
Neurological symptom (31)
Vasogenic cerebral oedema (31)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which MOSUNETUZUMAB Alternatives Have Lower Therapy partial responder Risk?
MOSUNETUZUMAB vs MOSUNETUZUMAB-AXGB
MOSUNETUZUMAB vs MOXIFLOXACIN
MOSUNETUZUMAB vs MOXIFLOXACIN\MOXIFLOXACIN
MOSUNETUZUMAB vs MOXONIDINE
MOSUNETUZUMAB vs MS CONTIN